United Therapeutics (UTHR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
47.3mn → 47.9mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
▲111% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$1.0B returned vs $1.0B of FCF in FY25. Buybacks covered by cash flow.
42¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 92.7% → 87.9%. Net margin 41.9% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,187.5 | 3,182.7 | 2,877.4 | 2,327.5 | 1,936.3 | 1,685.5 | ▲10.6% | +17.2% |
Cost of revenue | 435.4 | 384.4 | 309.7 | 257.5 | 151.6 | 122.5 | ▲24.1% | +33.1% |
Gross profit | 2,752.1 | 2,798.3 | 2,567.7 | 2,070.0 | 1,784.7 | 1,563.0 | ▲9.0% | +15.7% |
Research & development | 703.2 | 550.0 | 481.0 | 408.0 | 322.9 | 540.1 | ▲14.3% | +0.5% |
Selling, general & admin | 727.8 | 755.8 | 709.7 | 477.1 | 482.1 | 467.0 | ▲6.5% | +12.8% |
Total operating expenses | 1,431.0 | 1,305.8 | 1,190.7 | 885.1 | 805.0 | 1,007.1 | ▲9.7% | +6.7% |
Operating incomefeeds ROC rank | 1,321.1 | 1,492.5 | 1,377.0 | 1,184.9 | 979.7 | 555.9 | ▲8.4% | +28.0% |
Other income, net | 186.7 | 221.4 | 162.0 | 89.4 | −29.1 | 38.0 | — | — |
Pretax income | 1,507.8 | 1,713.9 | 1,539.0 | 1,274.3 | 950.6 | 593.9 | ▲11.4% | +30.3% |
Income tax | 277.0 | 379.2 | 343.9 | 289.5 | 223.3 | 118.1 | ▲10.3% | +33.9% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 1,230.8 | 1,334.7 | 1,195.1 | 984.8 | 727.3 | 475.8 | ▲11.7% | +29.4% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 26.46 | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 | ▲13.1% | +29.0% |
Diluted shares (mn) | 45.30 | 47.90 | 48.50 | 49.70 | 48.50 | 47.30 | ▼1.2% | +0.3% |
| Margins | ||||||||
Gross margin81st pct in Healthcare | 86.3% | 87.9% | 89.2% | 88.9% | 92.2% | 92.7% | ▼1.3pp | −4.8pp |
Operating margin | 41.4% | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | ▼1.0pp | +13.9pp |
Net margin98th pct in Healthcare | 38.6% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | ▲0.4pp | +13.7pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was United Therapeutics' revenue last fiscal year?
United Therapeutics reported revenue of $3,182.7M in fiscal 2025, up 10.6% from fiscal 2024.
What was United Therapeutics' net income?
United Therapeutics reported net income of $1,334.7M in fiscal 2025, a net margin of 41.9%.

